REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc. (Nasdaq: TZAC) filed an amended registration statement on January 7, 2021, in connection with its business combination with Tenzing Acquisition Corp, a blank-check company that completed its initial public offering in 2020. Tenzing Acquisition Corp targeted the healthcare and life sciences sector, and its proposed merger with Reviva Pharmaceuticals — a clinical-stage biopharmaceutical company developing treatments for central nervous system and metabolic disorders — marked the SPAC's intended business combination. At the time of the S-1/A filing, the transaction remained pending regulatory and shareholder approval. To access complete deal timelines, warrant data, and sponsor filings for TZAC and hundreds of other SPACs, sign up for full access at SpacDesk.